← Back to Search

Angiotensin II Type 1 Receptor Blocker

ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan) for Coronavirus (ARBs CORONA II Trial)

Phase 3
Waitlist Available
Led By James A Russell, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1, 3 and 6 months
Awards & highlights

ARBs CORONA II Trial Summary

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Eligible Conditions
  • Coronavirus

ARBs CORONA II Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1, 3 and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1, 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Acute cardiac injury
Days alive and free of vasopressors, ventilation, and renal replacement therapy
Hospital Mortality
+4 more

ARBs CORONA II Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan)Experimental Treatment8 Interventions
Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at initial or higher dose.
Group II: Usual Care ControlActive Control1 Intervention
Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Valsartan
2016
Completed Phase 4
~10560
Eprosartan
2012
Completed Phase 3
~690
Azilsartan
2012
Completed Phase 4
~6400
Candesartan
2005
Completed Phase 4
~11970
Olmesartan
2021
Completed Phase 4
~8630
Losartan
FDA approved
Irbesartan
2016
Completed Phase 4
~15260
Telmisartan
1999
Completed Phase 4
~14550

Find a Location

Who is running the clinical trial?

Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,338 Previous Clinical Trials
25,751,629 Total Patients Enrolled
University of British ColumbiaLead Sponsor
1,410 Previous Clinical Trials
1,766,230 Total Patients Enrolled
James A Russell, MDPrincipal InvestigatorUniversity of British Columbia
1 Previous Clinical Trials
500 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Jim Russell 2020. "Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04606563.
~76 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top